<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04268758</url>
  </required_header>
  <id_info>
    <org_study_id>Tulipon-HMO-CTIL</org_study_id>
    <nct_id>NCT04268758</nct_id>
  </id_info>
  <brief_title>A Single-center Study Designed to Evaluate the Safety and Efficacy of Tulipon</brief_title>
  <official_title>A Single-center Study Designed to Evaluate the Safety and Efficacy of a New Hygienic Device, Tulipon, in Adult Females With Normal Monthly Menstruation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ezra Yosi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects who normally use tampons will use Tulipon device during one menstrual cycle.
      Baseline and post usage clinical evaluation will be performed for safety testing.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>safety and efficacy of the Tulipon.</measure>
    <time_frame>1 month</time_frame>
    <description>We will take vaginal cultures to show no vaginal infection. By questionnaire we will find out about leakage of period blood from the Tulipon.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Safety Issues</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tulipon</intervention_name>
    <description>Tulipon is a new kind of hygienic device, used to collect the secreted menses during the bleeding phase of the menstruation.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult females with normal monthly menstruation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women aged 18-45 years

          2. Regular menstrual cycles (21-35 days)

          3. Uses tampons every month for the last 2 months to handle their monthly bleeding.

          4. Active Bleeding lasts at least 3 days

          5. Willing not to change their feminine care or hygiene practices during their
             participation in the study (except as directed by the protocol and instructions for
             participants)

          6. Non-pregnant, with no intentions to get pregnant during the clinical trial

          7. Willing to use pads provided thought the study only for the duration of this study

          8. Subject is able to comply with all the requirements of the study and agrees to
             participate in all the activities of the study

          9. Signed written informed consent form (ICF) to participate in the study

        Exclusion Criteria:

          1. Pregnant or lactating women

          2. Gave birth less than a 12 month prior to the study.

          3. Virgin

          4. Using medications to manage pain during active bleeding

          5. Using IUD or IUD with hormones (Mirena)

          6. Had experienced Toxic shock syndrome (TSS)

          7. Previous diagnosis of primary or secondary dysmenorrhea

          8. Previous diagnosis of endometriosis

          9. Experiences urinary incontinence

         10. Suffers from uterus or urine prolapse

         11. Abnormal findings following the gynecological exam

         12. Subjects with a known or suspected sensitivity to any of the device materials
             (Polyethylene, Polyurethane, Nylon, Cotton)

         13. Been through a vaginal operation in the last 6 months prior to the study.

         14. Participation in current or recent clinical trial within 30 days prior to baseline
             visit
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>women only.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>Ezra Yosi</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

